Cargando…
Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
Autores principales: | Montealegre, G, Reinhardt, A, Brogan, P, Berkun, Y, Zlotogorski, A, Brown, D, Chira, P, Gao, L, Dare, J, Schalm, S, Merino, R, Chapelle, D, Kim, H, Judd, S, O'Brien, M, De Jesus, A Almeida, Kim, Y, Kost, B, Huang, Y, Paul, S, Brofferio, A, Lee, C-C, Hadigan, C, Heller, T, Minniti, C, Rother, K, Goldbach-Mansky, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597264/ http://dx.doi.org/10.1186/1546-0096-13-S1-O31 |
Ejemplares similares
-
Histological and Immunohistochemical Features of the Skin Lesions in CANDLE Syndrome
por: Torrelo, A, et al.
Publicado: (2015) -
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
por: Jabbari, Ali, et al.
Publicado: (2015) -
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
por: Sanchez, Gina A. Montealegre, et al.
Publicado: (2018) -
Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)
por: Kanazawa, Nobuo, et al.
Publicado: (2023) -
The core of the candle problem.
por: Potera, C
Publicado: (2000)